883500-66-1

Basic information

• Product Name: 4-BROMO-7-FLUOROINDOLE
• Synonyms: 4-BROMO-7-FLUORO-1H-INDOLE;4-BROMO-7-FLUOROINDOLE;1H-INDOLE,4-BROMO-7-FLUORO
• CAS NO: 883500-66-1
• Molecular Formula: C₈H₅BrFN
• Molecular Weight: 214.03
• Mol File: 883500-66-1.mol

Chemical Properties

• Melting Point: 24-25℃
• Boiling Point: 314.2 °C at 760 mmHg
• Flash Point: 143.8 °C
• Appearance: /
• Density: 1.75 g/cm³
• Vapor Pressure: 0.000874mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Sparingly Soluble (0.28 g/L) (25°C)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-BROMO-7-FLUOROINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-7-FLUOROINDOLE(883500-66-1)
• EPA Substance Registry System: 4-BROMO-7-FLUOROINDOLE(883500-66-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 883500-66-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H5BrFN/c9-6-1-2-7(10)8-5(6)3-4-11-8/h1-4,11H

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 387-44-0 7-fluoro-1H-indole 
• 588688-52-2 7-fluoroindole-4-carboxylic acid 
• 1227502-83-1 4-bromo-7-fluoro-1H-indole-3-carbaldehyde 
• 1427423-19-5 (E)-methyl 1-(5-chloro-2-(4-chloro-2-fluorostyryl)benzyl)-1H-indole-4-carboxylate 
• 1427421-56-4 (E)-1-(5-chloro-2-(4-chloro-2-fluorostyryl)benzyl)-1H-indole-4-carboxylic acid 

Relevant articles and documents

Indole compound as well as preparation method, pharmaceutical composition and application thereof

The invention discloses an indole compound as well as a preparation method, a pharmaceutical composition and an application thereof. Specifically, the invention relates to an indole derivative as shown in a general formula I and a medicinal salt thereof, a preparation method of the indole derivative, a composition containing one or more compounds, and applications of the compounds in preparation of medicines for preventing and/or treating diseases related to IDO1 and/or TDO.

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1): and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1) useful as modulator of the activity of Aurora kinases and FLT3 kinases: and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer

Ep1 receptor ligands

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation,

EP1 RECEPTOR LIGANDS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

In search of simplicity and flexibility: A rational access to twelve fluoroindolecarboxylic acids

All twelve indolecarboxylic acids 1-12 carrying both a fluorine substituent and a carboxy group at the benzo ring have been prepared either directly from the corresponding fluoroindoles 13-16 or from the chlorinated derivatives 22, 23 and 25 by hydrogen/metal permutation ("metalation"), or from the bromo- or iodofluoroindoles 17-20 and 26, 27, 29 and 30 by halogen/metal permutation, the organometallic intermediate being each time trapped with carbon dioxide. In most, though not all cases, the nitrogen atom in the five-membered ring had to be protected by a trialkylsilyl group. Some of the bromo- or iodofluoroindoles (26 and 27) were successfully subjected to a basicity gradient-driven selective migration of the heavy halogen. An unexpected finding on the way to the target compounds were the rigorously site-selective metalation of the 5-fluoro-N-(trialkylsilyl)indole (14b; exclusive deprotonation of the 4-position). The fluoroindoles 13-16, although previously known, were accessed more conveniently from suitably substituted nitrobenzenes using the Bartoli or the Leimgruber-Batcho method. A new and very attractive indole synthesis was elaborated consisting of the ortho-lithiation of an N-acyl-protected aniline followed by ortho-formylation, Wittig chloromethylenation and base-catalyzed cyclization accompanied by dehydrochlorination. These five consecutive steps can be contracted to a convenient one-pot protocol. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.